tetano
Editor, Senior Moderator
J Clin Virol
. 2020 Jun 22;129:104521.
doi: 10.1016/j.jcv.2020.104521. Online ahead of print.
Multiplex Detection and Dynamics of IgG Antibodies to SARS-CoV2 and the Highly Pathogenic Human Coronaviruses SARS-CoV and MERS-CoV
Ahidjo Ayouba[SUP] 1 [/SUP], Guillaume Thaurignac[SUP] 2 [/SUP], David Morquin[SUP] 3 [/SUP], Edouard Tuaillon[SUP] 4 [/SUP], Raisa Raulino[SUP] 2 [/SUP], Antoine Nkuba[SUP] 2 [/SUP], Audrey Lacroix[SUP] 2 [/SUP], Nicole Vidal[SUP] 2 [/SUP], Vincent Foulongne[SUP] 5 [/SUP], Vincent Le Moing[SUP] 3 [/SUP], Jacques Reynes[SUP] 3 [/SUP], Eric Delaporte[SUP] 3 [/SUP], Martine Peeters[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Knowledge of the COVID-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic.
Methods: We used a panel of 167 samples (77 pre-epidemic and 90 COVID-19 seroconverters) and SARS-CoV1, SARS-CoV2 and MERS-CoV Spike and/or Nucleopcapsid (NC) proteins to develop a high throughput multiplex screening assay to detect IgG antibodies in human plasma. Assay performances were determined by ROC curves analysis. A subset of the COVID-19+ samples (n = 36) were also tested by a commercial NC-based ELISA test and the results compared with those of the novel assay.
Results: On samples collected ≥14 days after symptoms onset, the accuracy of the assay is 100 % (95 % CI: 100-100) for the Spike antigen and 99.9 % (95 % CI:99.7-100) for NC. By logistic regression, we estimated that 50 % of the patients have seroconverted at 5.7 ? 1.6; 5.7 ? 1.8 and 7.9 ? 1.0 days after symptoms onset against Spike, NC or both antigens, respectively and all have seroconverted two weeks after symptoms onset. IgG titration in a subset of samples showed that early phase samples present lower IgG titers than those from later phase. IgG to SARS-CoV2 NC cross-reacted at 100 % with SARS-CoV1 NC. Twenty-nine of the 36 (80.5 %) samples tested were positive by the commercial ELISA while 31/36 (86.1 %) were positive by the novel assay.
Conclusions: Our assay is highly sensitive and specific for the detection of IgG antibodies to SARS-CoV2 proteins, suitable for high throughput epidemiological surveys. The novel assay is more sensitive than a commercial ELISA.
Keywords: COVID-19; Luminex; SARS; SARS-CoV2; Serology.
. 2020 Jun 22;129:104521.
doi: 10.1016/j.jcv.2020.104521. Online ahead of print.
Multiplex Detection and Dynamics of IgG Antibodies to SARS-CoV2 and the Highly Pathogenic Human Coronaviruses SARS-CoV and MERS-CoV
Ahidjo Ayouba[SUP] 1 [/SUP], Guillaume Thaurignac[SUP] 2 [/SUP], David Morquin[SUP] 3 [/SUP], Edouard Tuaillon[SUP] 4 [/SUP], Raisa Raulino[SUP] 2 [/SUP], Antoine Nkuba[SUP] 2 [/SUP], Audrey Lacroix[SUP] 2 [/SUP], Nicole Vidal[SUP] 2 [/SUP], Vincent Foulongne[SUP] 5 [/SUP], Vincent Le Moing[SUP] 3 [/SUP], Jacques Reynes[SUP] 3 [/SUP], Eric Delaporte[SUP] 3 [/SUP], Martine Peeters[SUP] 2 [/SUP]
Affiliations
- PMID: 32623350
- PMCID: PMC7308014
- DOI: 10.1016/j.jcv.2020.104521
Abstract
Background: Knowledge of the COVID-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic.
Methods: We used a panel of 167 samples (77 pre-epidemic and 90 COVID-19 seroconverters) and SARS-CoV1, SARS-CoV2 and MERS-CoV Spike and/or Nucleopcapsid (NC) proteins to develop a high throughput multiplex screening assay to detect IgG antibodies in human plasma. Assay performances were determined by ROC curves analysis. A subset of the COVID-19+ samples (n = 36) were also tested by a commercial NC-based ELISA test and the results compared with those of the novel assay.
Results: On samples collected ≥14 days after symptoms onset, the accuracy of the assay is 100 % (95 % CI: 100-100) for the Spike antigen and 99.9 % (95 % CI:99.7-100) for NC. By logistic regression, we estimated that 50 % of the patients have seroconverted at 5.7 ? 1.6; 5.7 ? 1.8 and 7.9 ? 1.0 days after symptoms onset against Spike, NC or both antigens, respectively and all have seroconverted two weeks after symptoms onset. IgG titration in a subset of samples showed that early phase samples present lower IgG titers than those from later phase. IgG to SARS-CoV2 NC cross-reacted at 100 % with SARS-CoV1 NC. Twenty-nine of the 36 (80.5 %) samples tested were positive by the commercial ELISA while 31/36 (86.1 %) were positive by the novel assay.
Conclusions: Our assay is highly sensitive and specific for the detection of IgG antibodies to SARS-CoV2 proteins, suitable for high throughput epidemiological surveys. The novel assay is more sensitive than a commercial ELISA.
Keywords: COVID-19; Luminex; SARS; SARS-CoV2; Serology.